Meitav Investment House Ltd. Acquires 1,950,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Meitav Investment House Ltd. boosted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 82.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,305,674 shares of the company's stock after acquiring an additional 1,950,500 shares during the period. Meitav Investment House Ltd. owned 0.38% of Teva Pharmaceutical Industries worth $44,914,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its holdings in shares of Teva Pharmaceutical Industries by 1.6% during the first quarter. Bank of New York Mellon Corp now owns 1,875,394 shares of the company's stock worth $17,609,000 after acquiring an additional 28,920 shares during the period. PNC Financial Services Group Inc. boosted its stake in Teva Pharmaceutical Industries by 12.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 119,076 shares of the company's stock valued at $1,118,000 after purchasing an additional 13,069 shares during the period. MetLife Investment Management LLC grew its holdings in Teva Pharmaceutical Industries by 4.7% in the 1st quarter. MetLife Investment Management LLC now owns 95,953 shares of the company's stock valued at $901,000 after buying an additional 4,300 shares in the last quarter. BlackRock Inc. increased its position in Teva Pharmaceutical Industries by 3.7% during the 1st quarter. BlackRock Inc. now owns 41,648,716 shares of the company's stock worth $391,081,000 after buying an additional 1,494,814 shares during the period. Finally, Great West Life Assurance Co. Can increased its position in Teva Pharmaceutical Industries by 4.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 420,533 shares of the company's stock worth $4,137,000 after buying an additional 16,134 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Insiders Place Their Bets

In related news, CAO Amir Weiss sold 31,766 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CAO Amir Weiss sold 31,766 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the completion of the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at $132,062.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Mark Sabag sold 100,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total value of $1,352,000.00. Following the transaction, the executive vice president now directly owns 382,590 shares in the company, valued at $5,172,616.80. The disclosure for this sale can be found here. Insiders sold a total of 390,738 shares of company stock valued at $5,132,766 in the last 90 days. Corporate insiders own 0.62% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on TEVA shares. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price objective for the company in a research note on Friday, March 8th. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and raised their price objective for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. Barclays upped their target price on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an "overweight" rating in a research report on Monday, February 5th. HSBC assumed coverage on Teva Pharmaceutical Industries in a report on Monday, December 18th. They set a "buy" rating and a $13.00 target price on the stock. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 1st. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and a consensus price target of $13.78.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded up $0.01 during midday trading on Thursday, reaching $13.86. The company's stock had a trading volume of 9,571,029 shares, compared to its average volume of 10,701,212. The stock has a market cap of $15.54 billion, a PE ratio of -29.49, a price-to-earnings-growth ratio of 1.64 and a beta of 1.05. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23. Teva Pharmaceutical Industries Limited has a 52 week low of $7.09 and a 52 week high of $14.47. The business has a 50-day moving average price of $13.39 and a 200-day moving average price of $11.13.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.25. The company had revenue of $4.46 billion for the quarter, compared to analyst estimates of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. On average, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.